The core of our business model is to work with and support our asset partners, helping to fully realize the potential of their innovations and optimize their return on investment. Focusing 100% on Chinese patients, healthcare systems, and access, we are building best-in-class R&D and commercial platforms that ensure compliance, quality, and appropriate use of our medicines.
We welcome partners around the globe who share our vision. Our priority is to invest in clinical stage assets with demonstrated efficacy, or portfolios where multiple product opportunities and synergies exist. We are also interested in cutting-edge platforms where multiple products can be rapidly discovered and developed. Please contact us at: BD@briibio.com.
Brii Bio Partners
Brii Bio has established a partnership with Vir Biotechnology (www.vir.bio), a leading U.S.-based biotech working to find cures for infectious diseases, that grants Brii Bio options on exclusive greater China rights for up to four assets in Vir’s infectious diseases portfolio. This therapeutic pipeline holds the potential to prevent, treat, and cure a wide range of infectious diseases.
Brii Bio has signed a memorandum of understanding to create a first-of-its-kind partnership with Alihealth (www.alihealth.cn). We believe Alihealth’s digital and data capabilities and access to healthcare information will help us optimize clinical development, generate value-based evidence, and enable better market access for innovative medicines through patient education and physician support.
Brii Bio has established a long-term partnership with WuXi AppTec (www.wuxiapptec.com) and WuXi Biologics (www.wuxibiologics.com), or collectively WuXi, to gain priority access to its best-in-class end-to-end R&D capabilities. This will allow us to focus on building core competencies in key therapeutic areas and specific products. We will create a “one team” way of working with WuXi through our shared vision and commitment.